login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EQRX INC (EQRX) Stock News
USA
- NASDAQ:EQRX -
US26886C1071
-
Common Stock
2.34
USD
-0.05 (-2.09%)
Last: 11/8/2023, 8:00:02 PM
2.39
USD
+0.05 (+2.14%)
After Hours:
11/8/2023, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EQRX Latest News, Press Relases and Analysis
All
Press Releases
2 years ago - By: Bronstein, Gewirtz & Grossman, LLC
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
2 years ago - By: Kahn Swick & Foti, LLC
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
2 years ago - By: Robbins LLP
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
2 years ago - By: Benzinga
EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce
2 years ago - By: Benzinga
Earnings Outlook For EQRx
2 years ago - By: Brodsky & Smith LLC
- Mentions:
CPRI
AVID
TPR
RVMD
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)
2 years ago - By: Kahn Swick & Foti, LLC
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
2 years ago - By: Ademi LLP
Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines
2 years ago - By: Halper Sadeh LLC
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
2 years ago - By: Seeking Alpha
- Mentions:
RVMD
Revolution Medicines will buy EQRx in an all-stock transaction (NASDAQ:RVMD)
2 years ago - By: Revolution Medicines, Inc.; EQRx, Inc.
- Mentions:
RVMD
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital
2 years ago - By: Seeking Alpha
EQRx GAAP EPS of -$0.17 misses by $0.03 (NASDAQ:EQRX)
2 years ago - By: EQRx, Inc.
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
2 years ago - By: EQRx, Inc.
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
3 years ago - By: Robbins LLP
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
3 years ago - By: Seeking Alpha
EQRX stock lower as CFO departs (NASDAQ:EQRX)
3 years ago - By: Seeking Alpha
EQRx GAAP EPS of -$0.05 beats by $0.14 (NASDAQ:EQRX)
3 years ago - By: EQRx, Inc.
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
3 years ago - By: EQRx, Inc.
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 years ago - By: EQRx, Inc.
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
3 years ago - By: EQRx, Inc.
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
3 years ago - By: Seeking Alpha
- Mentions:
GS
EQRX stock extends post-earnings slump as Goldman Sachs, Jefferies downgrade (NASDAQ:EQRX)
Please enable JavaScript to continue using this application.